JP2006503807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006503807A5 JP2006503807A5 JP2004511287A JP2004511287A JP2006503807A5 JP 2006503807 A5 JP2006503807 A5 JP 2006503807A5 JP 2004511287 A JP2004511287 A JP 2004511287A JP 2004511287 A JP2004511287 A JP 2004511287A JP 2006503807 A5 JP2006503807 A5 JP 2006503807A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pharmaceutical preparation
- compound according
- drug
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- IFNXFIJXYVEYLF-UHFFFAOYSA-N 2-Propylglutaric acid Chemical compound CCCC(C(O)=O)CCC(O)=O IFNXFIJXYVEYLF-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010052804 Drug tolerance Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- PPTOPCBILCUEBB-UHFFFAOYSA-N O.CCCC(CCC(O)=O)C(O)=O Chemical compound O.CCCC(CCC(O)=O)C(O)=O PPTOPCBILCUEBB-UHFFFAOYSA-N 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 231100000040 eye damage Toxicity 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033300 perinatal asphyxia Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 0 *C(*[C@@]([C@]12)[C@@]1C(O)=O)[C@]2(C(O)=O)N Chemical compound *C(*[C@@]([C@]12)[C@@]1C(O)=O)[C@]2(C(O)=O)N 0.000 description 1
- PRSPRRUBXVJDRI-UHFFFAOYSA-N O=S(=O)=C1CCC2CC12 Chemical compound O=S(=O)=C1CCC2CC12 PRSPRRUBXVJDRI-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02380120 | 2002-06-11 | ||
| EP02380121 | 2002-06-11 | ||
| US41593702P | 2002-10-03 | 2002-10-03 | |
| US41593602P | 2002-10-03 | 2002-10-03 | |
| PCT/US2003/015405 WO2003104217A2 (en) | 2002-06-01 | 2003-06-06 | Prodrugs of excitatory amino acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008031490A Division JP2008201779A (ja) | 2002-06-11 | 2008-02-13 | 興奮性アミノ酸のプロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006503807A JP2006503807A (ja) | 2006-02-02 |
| JP2006503807A5 true JP2006503807A5 (https=) | 2008-04-03 |
| JP4342437B2 JP4342437B2 (ja) | 2009-10-14 |
Family
ID=29740902
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004511287A Expired - Lifetime JP4342437B2 (ja) | 2002-06-11 | 2003-06-06 | 興奮性アミノ酸のプロドラッグ |
| JP2008031490A Pending JP2008201779A (ja) | 2002-06-11 | 2008-02-13 | 興奮性アミノ酸のプロドラッグ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008031490A Pending JP2008201779A (ja) | 2002-06-11 | 2008-02-13 | 興奮性アミノ酸のプロドラッグ |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US7371872B2 (https=) |
| EP (2) | EP1517915B1 (https=) |
| JP (2) | JP4342437B2 (https=) |
| KR (1) | KR20080058509A (https=) |
| AR (1) | AR040257A1 (https=) |
| AT (1) | ATE421526T1 (https=) |
| AU (1) | AU2003232146B2 (https=) |
| BR (1) | BR0311558A (https=) |
| CA (1) | CA2488167C (https=) |
| CO (1) | CO5631438A2 (https=) |
| CR (2) | CR7616A (https=) |
| CY (1) | CY1108976T1 (https=) |
| DE (1) | DE60325968D1 (https=) |
| DK (1) | DK1517915T3 (https=) |
| EA (2) | EA014979B1 (https=) |
| EC (1) | ECSP085481A (https=) |
| ES (1) | ES2319116T3 (https=) |
| HR (2) | HRP20090058A2 (https=) |
| IL (2) | IL165100A0 (https=) |
| MX (1) | MXPA04012518A (https=) |
| MY (1) | MY146238A (https=) |
| NO (2) | NO331780B1 (https=) |
| NZ (3) | NZ564692A (https=) |
| PE (1) | PE20040555A1 (https=) |
| PL (1) | PL221489B1 (https=) |
| PT (1) | PT1517915E (https=) |
| SI (1) | SI1517915T1 (https=) |
| WO (1) | WO2003104217A2 (https=) |
| ZA (1) | ZA200409553B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1517915B1 (en) * | 2002-06-11 | 2009-01-21 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| PL2203439T3 (pl) | 2007-09-14 | 2011-06-30 | Addex Pharmaceuticals Sa | 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| RU2517181C2 (ru) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов |
| WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| WO2010111080A2 (en) | 2009-03-27 | 2010-09-30 | Eli Lilly And Company | Optimized treatment of schizophrenia |
| MY153912A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| ES2837121T3 (es) * | 2009-06-29 | 2021-06-29 | Inolex Investment Corp | Emulsionantes catiónicos derivados no petroquímicamente que son ésteres de aminoácidos neutralizados y composiciones y métodos relacionados |
| AR079343A1 (es) | 2009-12-21 | 2012-01-18 | Lilly Co Eli | Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico |
| CN103261195B (zh) | 2010-11-08 | 2015-09-02 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
| AR083845A1 (es) | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
| CN103209954B (zh) * | 2010-11-18 | 2015-09-02 | 伊莱利利公司 | 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物 |
| PT2721012T (pt) | 2011-06-17 | 2016-07-27 | Lilly Co Eli | Derivados do ácido biciclo(3.1.0)hexano-2,6¿dicarboxílico como agonista do recetor mglu2 |
| AR089718A1 (es) * | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
| US9428483B2 (en) | 2012-06-01 | 2016-08-30 | Taisho Pharmaceutical Co., Ltd. | Prodrug of fluorine-containing amino acid |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) * | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| KR20220049612A (ko) | 2014-01-21 | 2022-04-21 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| HUE053734T2 (hu) * | 2014-01-21 | 2021-07-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk |
| CN108774274B (zh) * | 2015-03-06 | 2020-11-03 | 北京大学 | 唾液酸甲酯甲苷衍生物及其合成方法和应用 |
| JP6801835B2 (ja) | 2015-07-09 | 2020-12-16 | ミメトゲン ファーマシュウティカルズ インコーポレイテッドＭｉｍｅｔｏｇｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | β−ターンペプチド模倣環状塩の液相合成及び結晶化 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US200488A (en) | 1878-02-19 | Improvement in temporary binders | ||
| US1459765A (en) * | 1922-03-18 | 1923-06-26 | Wordsworth M Elliott | Interchangeable sign letters |
| WO1993006127A1 (en) * | 1991-09-17 | 1993-04-01 | Warner-Lambert Company | Novel amino acid prodrug renin inhibitors |
| US5849525A (en) | 1994-03-09 | 1998-12-15 | Brigham And Women's Hospital, Inc. | Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same |
| DE69529209T2 (de) * | 1995-03-14 | 2003-11-13 | Brown & Sharpe Tesa S.A., Renens | Element mit einem geregelten Diodenlaser, und elektrooptische Vorrichtung unter Verwendung eines derartigen Elements |
| JP2000500748A (ja) * | 1995-11-16 | 2000-01-25 | イーライ・リリー・アンド・カンパニー | 興奮性アミノ酸誘導体 |
| US5688826A (en) * | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| ZA983930B (en) * | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
| ATE236118T1 (de) * | 1998-01-28 | 2003-04-15 | Taisho Pharmaceutical Co Ltd | Fluorhaltige aminosäurederivate |
| ATE269293T1 (de) * | 1998-08-31 | 2004-07-15 | Taisho Pharmaceutical Co Ltd | 6-fluoro(3.1.0)hexan-derivate |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6313498B1 (en) * | 1999-05-27 | 2001-11-06 | Actrans System Inc. | Flash memory cell with thin floating gate with rounded side wall, and fabrication process |
| AU6785401A (en) * | 2000-06-28 | 2002-01-08 | Taisho Pharmaceutical Co Ltd | Novel dicarboxylic acid derivatives |
| HUP0400620A3 (en) * | 2001-01-11 | 2012-09-28 | Lilly Co Eli | Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds |
| EP1351925A1 (en) * | 2001-01-11 | 2003-10-15 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| BR0210391A (pt) * | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
| CA2471642C (en) | 2001-12-27 | 2011-05-24 | Taisho Pharmaceutical Co., Ltd. | 6-fluorobicyclo[3.1.0]hexane derivatives |
| US20050192273A1 (en) * | 2002-04-03 | 2005-09-01 | Johnson Bryan G. | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| WO2003084610A1 (en) * | 2002-04-03 | 2003-10-16 | Eli Lilly And Company | Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist |
| EP1517915B1 (en) * | 2002-06-11 | 2009-01-21 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
-
2003
- 2003-06-06 EP EP03757266A patent/EP1517915B1/en not_active Expired - Lifetime
- 2003-06-06 CA CA2488167A patent/CA2488167C/en not_active Expired - Lifetime
- 2003-06-06 PT PT03757266T patent/PT1517915E/pt unknown
- 2003-06-06 BR BRPI0311558-5A patent/BR0311558A/pt not_active Application Discontinuation
- 2003-06-06 AU AU2003232146A patent/AU2003232146B2/en not_active Expired
- 2003-06-06 NZ NZ564692A patent/NZ564692A/en not_active IP Right Cessation
- 2003-06-06 JP JP2004511287A patent/JP4342437B2/ja not_active Expired - Lifetime
- 2003-06-06 PL PL374381A patent/PL221489B1/pl unknown
- 2003-06-06 AT AT03757266T patent/ATE421526T1/de active
- 2003-06-06 WO PCT/US2003/015405 patent/WO2003104217A2/en not_active Ceased
- 2003-06-06 MX MXPA04012518A patent/MXPA04012518A/es active IP Right Grant
- 2003-06-06 DE DE60325968T patent/DE60325968D1/de not_active Expired - Lifetime
- 2003-06-06 EA EA200801711A patent/EA014979B1/ru not_active IP Right Cessation
- 2003-06-06 SI SI200331575T patent/SI1517915T1/sl unknown
- 2003-06-06 ES ES03757266T patent/ES2319116T3/es not_active Expired - Lifetime
- 2003-06-06 EA EA200500007A patent/EA011231B1/ru not_active IP Right Cessation
- 2003-06-06 HR HR20090058A patent/HRP20090058A2/xx not_active Application Discontinuation
- 2003-06-06 KR KR1020087013701A patent/KR20080058509A/ko not_active Withdrawn
- 2003-06-06 NZ NZ556437A patent/NZ556437A/en not_active IP Right Cessation
- 2003-06-06 US US10/516,559 patent/US7371872B2/en not_active Expired - Lifetime
- 2003-06-06 HR HRP20041179AA patent/HRP20041179B1/hr not_active IP Right Cessation
- 2003-06-06 DK DK03757266T patent/DK1517915T3/da active
- 2003-06-06 EP EP07122014A patent/EP1897550A3/en not_active Withdrawn
- 2003-06-06 NZ NZ536459A patent/NZ536459A/en not_active IP Right Cessation
- 2003-06-09 MY MYPI20032147A patent/MY146238A/en unknown
- 2003-06-09 PE PE2003000574A patent/PE20040555A1/es not_active Application Discontinuation
- 2003-06-10 AR ARP030102065A patent/AR040257A1/es active IP Right Grant
-
2004
- 2004-11-08 IL IL16510004A patent/IL165100A0/xx not_active IP Right Cessation
- 2004-11-25 ZA ZA2004/09553A patent/ZA200409553B/en unknown
- 2004-12-07 CO CO04122695A patent/CO5631438A2/es not_active Application Discontinuation
- 2004-12-09 CR CR7616A patent/CR7616A/es unknown
-
2005
- 2005-01-10 NO NO20050122A patent/NO331780B1/no not_active IP Right Cessation
-
2008
- 2008-02-07 IL IL189355A patent/IL189355A/en not_active IP Right Cessation
- 2008-02-12 NO NO20080765A patent/NO20080765L/no not_active Application Discontinuation
- 2008-02-13 JP JP2008031490A patent/JP2008201779A/ja active Pending
- 2008-03-31 US US12/059,112 patent/US7671082B2/en not_active Expired - Lifetime
- 2008-04-03 EC EC2008005481A patent/ECSP085481A/es unknown
-
2009
- 2009-04-07 CY CY20091100411T patent/CY1108976T1/el unknown
-
2010
- 2010-01-15 US US12/688,074 patent/US7964632B2/en not_active Expired - Lifetime
-
2011
- 2011-03-10 CR CR20110130A patent/CR20110130A/es not_active Application Discontinuation
- 2011-05-04 US US13/100,642 patent/US8153683B2/en not_active Expired - Fee Related
-
2012
- 2012-03-13 US US13/418,613 patent/US20120172422A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503807A5 (https=) | ||
| TW513416B (en) | Pyrazine compounds and pharmaceutical composition thereof useful as sodium channel blocker | |
| JP2024050607A (ja) | 結晶性の置換シクロヘキシルピラゾロ［１，５－ａ］ピリミジニルカルボキサミド化合物およびその治療的使用 | |
| JP7279758B2 (ja) | テトラヒドロナフタレン誘導体 | |
| MXPA05000435A (es) | Derivados de azabiciclo como antagonistas de receptor muscarinico. | |
| JP2004527467A5 (https=) | ||
| JPH06508816A (ja) | （ｓ）（＋）−２−エトキシ−４−［ｎ−［１−（２−ピペリジノ−フェニル）−３−メチル−１−ブチル〕アミノカルボニルメチル〕−安息香酸、この化合物を含む医薬組成物及びその調製方法 | |
| JPWO2002010101A1 (ja) | アミド化合物を配位子とする遷移金属錯体を用いたアルコールの製造方法 | |
| CN1832949A (zh) | 二肽基肽酶－iv抑制剂的磷酸盐 | |
| KR101369126B1 (ko) | 탄소환 ｇｌｙｔ1 수용체 길항제 | |
| KR102067850B1 (ko) | 하이드록실화 사이클로펜틸피리미딘 화합물 제조 방법 | |
| CA2540768A1 (en) | Pyrazolo and imidazo-pyrimidine derivatives | |
| CA2554536A1 (en) | Crystalline forms of gaboxadol monohydrate or anhydrate | |
| WO2017190609A1 (zh) | 一种高效合成西他沙星中间体(7s)-5-氮杂螺[2.4]庚烷-7-基氨基甲酸叔丁酯的制备方法 | |
| CA2873658C (en) | Process for making amino acid compounds | |
| JP7354960B2 (ja) | Ｓ１ｐ５介在性疾患の予防および／または治療剤 | |
| DE69621877T2 (de) | 4-Indolylpiperazinyl-Derivate | |
| WO2010000196A1 (zh) | 一种奥卡西平的化学合成方法 | |
| JPWO2010055911A1 (ja) | ビフェニルアセトアミド誘導体 | |
| JPH02169558A (ja) | 心臓および循環器疾患の治療薬および新規ニトロキシアルキルアミン誘導体 | |
| JP2007517009A (ja) | トルテロジン、その組成物及び使用、及びその製造方法 | |
| CN1083843C (zh) | 2－(氨基甲基)－3,4,7,9－四氢－2H－吡喃并[2,3－e]吲哚－8－酮及其衍生物和药物组合物 | |
| JP2004524292A5 (https=) | ||
| CA2433667A1 (en) | Prodrugs of excitatory amino acids | |
| EP0489548B1 (en) | A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof |